GeneEdit Therapeutics

Executive Summary

GeneEdit Therapeutics is a preclinical-stage gene editing company leveraging CRISPR technology to develop one-time curative therapies for inherited disorders. With a focus on rare diseases and ophthalmology, the company aims to correct disease-causing mutations with high precision. Founded in 2016 and headquartered in San Francisco, GeneEdit has raised approximately $500 million, reflecting strong investor confidence in its platform. The company's mission is to translate groundbreaking gene editing science into transformative treatments, addressing significant unmet medical needs. Currently, GeneEdit is advancing its pipeline toward the clinic, with several programs in late preclinical development.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead Ophthalmology Program70% success
• Q1 2027Preclinical Proof-of-Concept Data for Rare Disease Candidate80% success
• Q4 2026Potential Strategic Partnership or Licensing Deal60% success